BPC-157 Dosing Protocols: What Actually Works (2026 Guide)

What Is the Correct BPC-157 Dosage?

The standard BPC-157 dosage is 250-500 mcg injected subcutaneously once or twice daily for 4-8 weeks, adjusted for injury type, body weight, and reconstitution concentration. Most researchers start at 250 mcg once daily, confirm mcg-per-ml concentration before every draw, and cycle 6-8 weeks on with 4-6 weeks off between rounds for full recovery.

The most common BPC-157 dosing error is not choosing the wrong amount. It is running a protocol without knowing the concentration you created during reconstitution, which means every dose you draw is a guess. Get the math right and everything else becomes straightforward. Get it wrong and you are injecting an unknown quantity of an expensive peptide into an injury that deserves precision, not approximation.

This guide covers the complete BPC-157 dosing picture: mechanism of action, reconstitution and concentration math, a quick-reference dosing table, goal-specific protocols by condition and body weight, arginate versus acetate salt forms, evidence strength per claim, side effects and who should avoid it, common dosing mistakes, sourcing verification, WADA and regulatory status, and stack options.

This content is for educational purposes only. These compounds are intended for research use. Consult a qualified clinician before beginning any peptide protocol.

BPC-157 Dose Quick-Reference Table

If you only need the numbers, start here. This table captures the most-searched BPC-157 dosage and BPC-157 dose variants in one place: daily dose, weekly total, and duration by goal. This is the fastest way to answer "what is the BPC-157 dosing for my situation" without reading the full mechanism breakdown below.

Every row above assumes a verified concentration after reconstitution. The dosing table means nothing if your draw volume is a guess, which is why the reconstitution section below matters more than the numbers themselves.

BPC-157 Dosage by Body Weight

Most published protocols use a flat dose rather than a strict mg-per-kg formula, but bigger frames generally sit at the higher end of a given range. Use this table as a starting reference, then adjust based on how your injury responds over the first 2 weeks.

What Is BPC-157 and How Does It Work?

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide made of 15 amino acids, derived from a fragment of a protective protein found in human gastric juice. Unlike many peptides, it holds up in acidic environments and at room temperature for short periods, which is part of why it works both as an injectable and, in some forms, orally.

Three mechanisms drive most of what BPC-157 is used for. First, it upregulates growth hormone receptor expression at the tendon-to-bone junction, making tissue more responsive to endogenous growth signals. Second, it activates the FAK-paxillin signalling pathway, which drives fibroblast migration, survival under oxidative stress, and outgrowth from tendon explants; this was demonstrated directly in tendon fibroblast cultures by Chang 2011. Third, it upregulates VEGFR2 and activates the VEGFR2-Akt-eNOS pathway, accelerating blood vessel formation and blood flow recovery in ischaemic tissue, a mechanism confirmed in endothelial cell culture and rat hind-limb ischaemia models by Hsieh 2017. Separately, work on peripheral nerve injury found BPC-157 accelerated functional recovery after traumatic nerve crush in rat models, pointing to a fourth application beyond soft tissue by Gjurasin 2010.

These same mechanisms explain why BPC-157 shows up in tendon, ligament, muscle, gut mucosa, and nerve repair research. They also explain the safety question addressed further down this page: a peptide that drives new blood vessel growth and fibroblast migration is doing exactly what an injury needs, but the same pathway raises a legitimate question in anyone with active or undiagnosed cancer.

How Strong Is the Evidence, Claim by Claim?

Evidence quality varies a lot depending on which BPC-157 claim you are looking at, and treating all of it as equally solid is a mistake. Tendon and ligament healing has the deepest preclinical base, including direct fibroblast-level mechanism work. Gut mucosal repair has a long track record dating back to the original gastric-protection research this peptide was isolated from. Nerve recovery and vascular repair sit on fewer but still direct animal studies. Human clinical trial data remains the weak link across every application.

A large preclinical toxicity program run across mice, rats, rabbits, and dogs found BPC-157 well tolerated with no serious treatment-related toxicity, no identifiable lethal dose, and no genotoxic or teratogenic signal, which is the strongest safety data point available by Xu 2020. That same body of work fed into an early-phase human trial registration (NCT02637284) that was later withdrawn before results were reported, which is why anyone telling you BPC-157 is "clinically proven" in humans is overstating the record. The honest summary: strong mechanistic and animal evidence, essentially no completed human efficacy trials.

Reconstitution and Concentration Calculation

Reconstitution is the single most important skill in any peptide dosing protocol. An error here invalidates every subsequent dose calculation, and it is the step most people rush.

Equipment checklist

• BPC-157 lyophilised vial (confirm mg amount on label)
• Bacteriostatic water (BAC water) for injection, 30 ml supply minimum
• 1 ml or 2 ml luer-lock syringe for reconstitution
• 29-31 gauge, 0.5 inch insulin syringe for drawing and injecting
• Alcohol swabs
• Sharps container

Standard reconstitution formula

The formula: (BAC water added in ml) x 1000 / (peptide amount in mcg) = mcg per ml. To find units to draw on an insulin syringe: desired dose in mcg / concentration in mcg per ml x 100 = units.

Most researchers default to a 1000 mcg/ml concentration because the unit math is simple: 25 units = 250 mcg, 50 units = 500 mcg. Store reconstituted vials refrigerated at 2-8 degrees Celsius, and most sources report stability for 30-60 days once reconstituted, provided you avoid repeated freeze-thaw cycles. For the full walkthrough with photos, see How to Reconstitute Peptides.

Standard BPC-157 Dosing Protocol, Step by Step

1. Confirm concentration first. Run the reconstitution formula above before you draw a single unit. Write the mcg/ml number on the vial with a marker.
2. Pick your daily dose band. 250 mcg once daily for general recovery, 250-500 mcg twice daily for an active tendon, ligament, or joint injury.
3. Inject in the morning before food, or split AM and PM if running twice daily. For gut-focused protocols, oral capsules 20-30 minutes before meals maximise mucosal contact time. See our full breakdown of oral versus injectable BPC-157 for which delivery method fits your goal.
4. Rotate injection sites for systemic protocols, or inject near the injury site for localized joint and tendon work. Alternate left and right sides day to day.
5. Hold the dose steady for 2 weeks before adjusting. BPC-157 works on a slower tissue-remodeling timeline than a stimulant; judging it at day 3 tells you nothing.
6. Run 6-8 weeks on, then take 4-6 weeks off. This is the standard BPC-157 dosing cycle length reported across most protocols, giving tissue time to consolidate gains before the next round.
7. Reassess at week 4 and week 8. If pain, range of motion, or function has not moved by week 4, the dose or delivery method needs adjusting rather than extending the same protocol blindly.

BPC-157 Dosage, Dose, and Dosing: Clearing Up the Terms

"BPC-157 dosage," "BPC-157 dose," and "BPC-157 dosing" all refer to the same thing: how much peptide you administer per injection and how often. There is no meaningful difference between these terms in practice. What matters is that your dose is always expressed relative to your verified concentration, not a generic number pulled from a forum post. A 250 mcg BPC-157 dose from a 1000 mcg/ml vial is 25 units on an insulin syringe. That same 250 mcg dose from a 2500 mcg/ml vial is only 10 units. Confusing the two is the single most common way people double or triple their intended BPC-157 dosing without realizing it.

Arginate Salt vs Acetate Salt: Does It Change the Dose?

BPC-157 is sold as either an arginate or acetate salt, and this affects stability more than dosing. Arginate salt is generally considered more stable in solution and has become the more common form in circulation. The mcg amount on the label refers to the peptide itself in both cases, so the dosing math above applies the same way regardless of salt form. What changes is shelf life after reconstitution: arginate tends to hold up slightly longer under refrigeration.

Side Effects and Safety Profile

Reported side effects at standard 250-500 mcg dosing are mild and infrequent: injection site redness, mild fatigue, headache, and occasional nausea at higher oral doses. Serious adverse events have not been reported in the preclinical toxicity literature, which found no identifiable lethal dose across four species by Xu 2020. That said, "no serious toxicity in animal models" is not the same as "proven safe in humans long-term," and anyone with a personal or family history of cancer should treat the angiogenic mechanism above as a genuine reason to talk to a qualified clinician before starting.

Who Should Avoid BPC-157

• Anyone with active, suspected, or a strong personal/family history of cancer, given the pro-angiogenic mechanism.
• Pregnant or breastfeeding women; no adequate human safety data exists.
• Competitive athletes tested under WADA, NFL, UFC, NCAA, or similar codes. BPC-157 is a Section S0 non-approved substance, prohibited at all times, and detectable via mass spectrometry protocols developed specifically for anti-doping testing. See our full breakdown in is BPC-157 banned by WADA.
• Anyone currently on blood thinners without medical supervision, given the vascular mechanism.
• Anyone unwilling or unable to verify source purity through third-party testing before injecting.

Common BPC-157 Dosing Mistakes

1. Guessing concentration instead of calculating it. This is the mistake that invalidates everything else. Always run the reconstitution formula and write the number down.
2. Judging the protocol too early. Tissue remodeling takes weeks, not days. Give any dose band a full 2-4 weeks before deciding it isn't working.
3. Never cycling off. Running BPC-157 continuously for months without a break is not supported by any published protocol. Stick to 6-8 weeks on, 4-6 off.
4. Injecting the wrong site for the goal. Systemic recovery goals tolerate rotation; localized joint or tendon injuries respond better to injection near the affected structure.
5. Skipping source verification. Underdosed or contaminated vials are a real and documented problem in the peptide space. Always check a certificate of analysis before you inject anything.
6. Stacking blind. Adding a second peptide without understanding how the mechanisms overlap or compound side effects is how people end up with an intolerable protocol they can't troubleshoot.

How to Verify a BPC-157 Source

Sourcing is where most dosing protocols quietly fail before the peptide ever reaches a syringe. An underdosed vial makes every calculation above meaningless, no matter how precise your math is. Before you buy, check for a batch-specific third-party certificate of analysis (COA), confirm the vendor tests for purity and identity (not just "in-house" claims), and cross-reference the listed mg amount against the COA's actual measured content. We keep a running, vendor-neutral breakdown of what a legitimate COA should include and how to spot a fabricated one at our recommended sources page. For a deeper look at verification red flags, see how to know if peptides are real and the peptide purity crisis.

BPC-157 Stack Options

BPC-157 is frequently paired with other recovery peptides depending on the injury. For soft tissue and tendon-heavy rehab, the most discussed combination pairs it with TB-500, sometimes called the Wolverine stack; see our full TB-500 dosage guide for the companion protocol. For skin and connective tissue support, some researchers layer in GHK-Cu for wound healing. For knee-specific rehab work, our cartilage and osteoarthritis protocol walks through a BPC-157-inclusive stack in more detail. Whatever you combine it with, change one variable at a time so you can actually tell what's working.

Is BPC-157 Legal? Regulatory Status in 2026

BPC-157 has no FDA approval for human therapeutic use in the United States and is not eligible for compounding under 503B rules. It is not a scheduled controlled substance, so possession for personal research use is not criminalized the way a scheduled drug would be, but it also cannot be legally sold as a dietary supplement or marketed with a therapeutic claim. Competitive athletes should treat it as fully off-limits regardless of legal status outside of sport, since WADA's S0 category ban carries no therapeutic use exemption.

Frequently Asked Questions

Straight answers to the questions we get most about BPC-157 dosage, dose, and dosing.